First Patient Dosed with Gadeta’s gamma delta TCR Cell Therapy

GDT-002 is a potential first-in-class cellular immunotherapy

UTRECHT, Netherlands and BOSTONJuly 6, 2021 /PRNewswire/ — Gadeta B.V., a clinical-stage company developing innovative, gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for cancer patients, today announced the dosing of the first patient with GDT-002 (formerly labelled TEG002), a potential first-in-class cellular immunotherapy for the treatment of cancer.

The multicenter phase 1/2 study in collaboration with the Dana-Farber Cancer Institute, Mass General Brigham Cancer Care and Beth Israel Deaconess Medical Center, is evaluating safety, tolerability and preliminary efficacy of GDT-002 for the treatment of multiple myeloma (MM).

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH